Disease Activity Patterns of Paediatric Inflammatory Bowel Disease: A Danish Nationwide Cohort Study (1996–2018)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background and Aims
Inflammatory bowel diseases [IBD] are heterogeneous in the frequency and severity of their flare-ups. We aimed to describe disease activity patterns in a Danish nationwide paediatric IBD cohort.

Methods
Paediatric patients [<18 years at diagnosis] with Crohn’s disease [pCD] or ulcerative colitis [pUC] in the study period from 1996 to 2018 were identified in national registers. Disease activity [severe, moderate-to-mild, remission] was assessed at diagnosis according to medications prescribed, hospitalizations, and surgeries.

Results
In total, 1965 pCD and 1838 pUC incident patients were included in the cohort. At diagnosis, severe disease activity was found in 87%/80% of pCD/pUC and in addition 6.1% of pUC patients had undergone a colectomy during the first year after diagnosis. Five years after diagnosis, the annual proportions of pCD/pUC with no disease activity were 70%/61%, and 10 years after diagnosis the proportions were 72%/64%. Colectomy was required in 6.1, 12, and 16% of pUC patients after 1, 5 and 10 years. No improvement of disease activity was seen in the proportion of prevalent pCD [N = 2515] and pUC [N = 2428] in the study period 2000–2018 concomitant with the introduction of biological treatment. However, decreasing disease activity was the most common pattern in both pCD and pUC [43 and 47%], respectively.

Conclusions
pIBD was characterized by a high proportion of patients with severe activity at diagnosis, followed by an improvement after 5 and 10 years of follow-up. Notably, the proportion of patients with no disease activity was unchanged when biological treatment was introduced and the number of colectomies in pUC remained high.
OriginalsprogEngelsk
TidsskriftJournal of Crohn's and Colitis
Vol/bind18
Udgave nummer2
Sider (fra-til)246-255
Antal sider10
ISSN1873-9946
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
MDW: grants from Novo Nordisk Foundation and Bristol Meyers Squibb, unrelated to the work submitted.SJ, MM, VW: no disclosures relating to the work submitted. JB: personal fees from AbbVie, Janssen-Cilag, Celgene, and Pfizer. Grants and personal fees from MSD. Grants and personal fees from Takeda for participating in advisory boards. Grants and personal fees from Tillotts Pharma. Personal fees from Samsung Bioepis. Grants from Bristol Myers Squibb and Novo Nordisk. All unrelated to the work submitted.

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved.

ID: 386613602